Abstract: An ophthalmic drug delivery carrier includes a resveratrol-encapsulating poly(?-caprolactone) (PCL) nanoparticle, metformin grafted on a surface of the resveratrol-encapsulating PCL nanoparticle, and a transacting activator of transcription (TAT) peptide grafted on the surface of the resveratrol-encapsulating PCL nanoparticle. A method for preparing the ophthalmic drug delivery carrier and a method for alleviating macular degeneration using the ophthalmic drug delivery carrier are also provided.

Abstract: Disclosed herein is a method for alleviating dry eye syndrome using a composition containing a polylysine nanoparticle. The polylysine nanoparticle is produced by subjecting lysine hydrochloride to a pyrolysis treatment at a temperature ranging from 240° C. to 280° C.

Abstract: A nanosphere includes a metal oxide hollow nanosphere and a poly-L-histidine. The metal oxide is selected from the group consisting of cerium(IV) oxide (CeO2), aluminum oxide (Al2O3), copper(II) oxide (CuO), titanium dioxide (TiO2), sodium oxide (Na2O), zinc oxide (ZnO), gold(II) oxide (AuO), iron(II, III) oxide (Fe3O4), and combinations thereof. The poly-L-histidine is grafted on a surface of the metal oxide hollow nanosphere. A drug delivery carrier including the nanosphere, and a method for alleviating an anterior segment eye disease using the drug delivery carrier are also disclosed.

Abstract: Disclosed herein is a method for alleviating dry eye syndrome using a composition containing a polylysine nanoparticle. The polylysine nanoparticle is produced by subjecting lysine hydrochloride to a pyrolysis treatment at a temperature ranging from 240° C. to 280° C.

Abstract: Disclosed herein is a carbon quantum dot produced by the step of subjecting dopamine and spermine to a pyrolysis treatment at 250° C. Also disclosed herein is use of the carbon quantum dot for treating a bacterial infection, and for inhibiting bacterial growth and biofilm formation.

Abstract: Disclosed herein is a carbon quantum dot produced by the step of subjecting dopamine and spermine to a pyrolysis treatment at 250° C. Also disclosed herein is use of the carbon quantum dot for treating a bacterial infection, and for inhibiting bacterial growth and biofilm formation.

Abstract: Disclosed herein is an ocular drug delivery system, comprising a positively charged chitosan-modified hydrogel, a secretory phospholipase A2 (sPLA2) hydrolysable liposome encapsulating an anti-inflammatory drug and having a negative surface charge, a first thiolated hyaluronic acid (HA-SH) nanoparticle encapsulating a wound-healing drug and having a negative surface charge, and a second HA-SH nanoparticle encapsulating a transforming growth factor-? inhibitor and having a negative surface charge. The sPLA2 hydrolysable liposome and the first and second HA-SH nanoparticles are attached to the positively charged chitosan-modified hydrogel by electrostatic attraction. Uses of the system are also disclosed.

Abstract: Disclosed herein is an ocular drug delivery system, comprising a positively charged chitosan-modified hydrogel, a secretory phospholipase A2 (sPLA2) hydrolysable liposome encapsulating an anti-inflammatory drug and having a negative surface charge, a first thiolated hyaluronic acid (HA-SH) nanoparticle encapsulating a wound-healing drug and having a negative surface charge, and a second HA-SH nanoparticle encapsulating a transforming growth factor-? inhibitor and having a negative surface charge. The sPLA2 hydrolysable liposome and the first and second HA-SH nanoparticles are attached to the positively charged chitosan-modified hydrogel by electrostatic attraction. Uses of the system are also disclosed.

Abstract: A method for manufacturing a hollow particle is provided. The method comprises the steps of (a) providing a hollow particulate; (b) soaking the hollow particulate in an amine solution to form amine groups on the surface of the hollow particulate; (c) adding a polypeptide, and the polypeptide is linked to the amine groups on the surface of the hollow particulate; and (d) adding a target molecule, and the target molecule is bound to the amine group which are still not bound.

Abstract: A method for manufacturing a hollow particle is provided. The method comprises the steps of (a) providing a hollow particulate; (b) soaking the hollow particulate in an amine solution to form amine groups on the surface of the hollow particulate; (c) adding a polypeptide, and the polypeptide is linked to the amine groups on the surface of the hollow particulate; and (d) adding a target molecule, and the target molecule is bound to the amine group which are still not bound.

Abstract: A hollow particle is provided. The hollow particle of the invention comprises (a) a hollow microparticle, (b) a plural of linking molecules binding the surface of the microparticle, (c) a polypeptide binding the linking molecule, and (d) a target molecule binding the linking molecule. The hollow microparticle of the invention can deliver more cells and provides a higher rate of cell transplantation by the hollow structures, polypeptides and target molecules. The present invention also provides a manufacture of the hollow microparticle and a cell carrier.

Abstract: A method of forming cell spheroids cultured in a serum-free manner on nanoscale coatings of hyaluronic acid with high molecular weight is disclosed. Corneal stromal cells are cultured on the hyaluronic acid coatings with nanotopography in the serum-free manner. Experimental results show that the cells cultured on the hyaluronic acid coatings (1.1-1.7 nm) increase cell-cell interaction, and when the cells form three-dimensional spheroids, they have higher biological synthetic capabilities and can secret more extracellular matrix, which has potential applications in corneal stromal tissue reconstruction.

Abstract: Disclosed herein are a hydrogel-forming polymer and a process of making the same. Also disclosed are a sustained-release pharmaceutical composition that contains a therapeutic agent and the aforesaid hydrogel-forming polymer, and a method for treating or preventing an ophthalmic disorder, which includes intraocularly administering into an eye of a mammal in need of such treatment a sustained-release pharmaceutical composition that contains an ophthalmic drug and the aforesaid hydrogel-forming polymer.

Abstract: A biopolymer-bioengineered human corneal endothelial cell (HCEC) sheet construct for reconstructing corneal endothelium in a patient is recited. The construct includes a biopolymer carrier which is bioresorable and deformable; and a bioengineered cell sheet containing a monolayer of interconnected HCECs with substantially uniform orientation. The bioengineered cell sheet is attached to a surface of the biopolymer carrier with apical surfaces of the HCECs facing said carrier.

Abstract: The present invention discloses a biopolymer-bioengineered human corneal endothelial cell (HCEC) sheet construct for reconstructing corneal endothelium in a patient. The construct includes a biopolymer carrier which is bioresorable and deformable; and a bioengineered cell sheet comprising a monolayer of interconnected HCECs with substantially uniform orientation, wherein the bioengineered cell sheet is attached to a surface of the carrier with apical surfaces of the HCECs facing said carrier.

Abstract: A method for accessing a non-volatile memory by both PC and X-BOX is disclosed. The method includes the following steps: initializing a memory controller, preferably with a USB interface, for accessing the non-volatile memory; generating the first logical-to-physical address mapping table for mapping the first portion of the non-volatile memory; configuring the controller; monitoring the occurrence of an event; analyzing the starting logic address specified in a token packet sent from the host to the controller in response to the event; and generating the second logical-to-physical address mapping table for mapping the second portion of the non-volatile memory when its starting logic address is absent in the first logical-to-physical address mapping table.